Codexis, Inc. (CDXS)

Market Cap	155.50M -36.9%
Revenue (ttm)	77.68M +35.9%
Net Income	-30.72M
EPS	-0.34
Shares Out	109.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,010,688
Open	1.480
Previous Close	1.475
Day's Range	1.410 - 1.500
52-Week Range	0.958 - 2.980
Beta	2.50
Analysts	Buy
Price Target	6.33 (+345.78%)
Earnings Date	Aug 11, 2026

About CDXS

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The co...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 22, 2010
• Employees: 146
• Stock Exchange: NASDAQ
• Ticker Symbol: CDXS
• Website: https://www.codexis.com

Financial Performance

In 2025, Codexis's revenue was $70.39 million, an increase of 18.61% compared to the previous year's $59.35 million. Losses were -$43.97 million, -32.63% less than in 2024.

Analyst Summary

According to 7 analysts, the average rating for CDXS stock is "Buy." The 12-month stock price target is $6.33, which is an increase of 345.78% from the latest price.

Price Target

$6.33

(345.78% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 4, 2026

Data Sources Report a data error